8-K: VBI Vaccines Sells Manufacturing Assets and Licenses to Brii Biosciences in Debt Reduction Move

VBI Vaccines has entered into agreements with Brii Biosciences to sell manufacturing capabilities, intellectual property, and grant licenses, aiming to reduce debt and streamline operations.

Summary

• VBI Vaccines has agreed to sell its manufacturing capabilities in Rehovot, Israel, along with intellectual property related to VBI-2601, and grant an exclusive license for VBI-1901 in the Asia Pacific region (excluding Japan) to Brii Biosciences.
• The total consideration for these transactions could reach up to $33 million, contingent on the completion of certain activities.
• VBI will receive an initial $2.5 million, with the remaining $30.5 million tied to the completion of specific milestones, targeted for June 30, 2024.
• The proceeds from these transactions will be used to reduce VBI's debt with K2 HealthVentures, which is expected to decrease to $17 million upon full completion.
• The agreement also includes amendments to previous collaboration agreements with Brii Bio, removing royalty and milestone payment obligations for Brii Bio and granting perpetual licenses for certain technologies.
• A key part of the deal involves VBI completing 'Essential Activities' to transfer manufacturing responsibilities for VBI-2601 and PreHevbri to Brii Bio.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the significant debt reduction and strategic asset sales, but there are risks associated with the completion of the transaction and the loss of future revenue streams. The company is taking steps to improve its financial position, which is viewed favorably.

Positives

• The transaction is expected to significantly reduce VBI's debt by approximately 70%, bringing it down to $17 million.
• The deal provides VBI with an immediate cash injection of $2.5 million and the potential for an additional $30.5 million.
• The sale of assets and licensing agreements will streamline VBI's operations and allow for a more focused resource deployment.
• The removal of royalty and milestone payment obligations for Brii Bio simplifies the financial structure of the collaboration.
• The agreement allows VBI to focus on its core pipeline and development programs.

Negatives

• VBI is selling key assets, including its manufacturing facility and intellectual property for VBI-2601.
• The company is giving up future royalty and milestone payments from Brii Bio for certain products.
• The deal is contingent on VBI completing 'Essential Activities' which could introduce execution risk.
• The full $33 million consideration is not guaranteed and is dependent on achieving certain milestones.

Risks

• The transaction is subject to the completion of certain activities and approvals, which may not be achieved.
• VBI's ability to complete the 'Essential Activities' and transfer manufacturing responsibilities to Brii Bio is critical for the deal's success.
• The company's financial stability remains dependent on the successful execution of this transaction and its ability to manage its remaining debt.
• There is a risk that the company may not be able to secure future funding for its development programs.
• The company is exposed to general economic, industry, and political risks, as well as the ongoing impact of the COVID-19 pandemic.

Future Outlook

VBI expects that this transaction will improve its financial stability, reduce its long-term burn rate, and reduce its debt overhang by about 70%. The company believes this deal better positions it to deliver on its mission and focus on its pipeline.

Management Comments

• Jeff Baxter, President and CEO of VBI, stated that the transaction improves the financial stability of VBI and balances potential value creation with a streamlined and focused resource deployment.
• Management anticipates that the company will have reduced its long-term burn and debt overhang by about 70% upon successful completion of all transactions.
• Management believes that the company's pipeline can have a meaningful impact on patients, providers, and public health.

Industry Context

This announcement reflects a trend in the biotech industry where companies are seeking strategic partnerships and asset sales to manage debt and focus on core development programs. The deal with Brii Biosciences allows VBI to monetize assets and reduce financial risk, while Brii gains access to valuable intellectual property and manufacturing capabilities.

Comparison to Industry Standards

• The sale of manufacturing facilities and licensing of intellectual property is a common strategy for biotech companies facing financial constraints, similar to companies like Novavax who have sold manufacturing facilities to raise capital.
• The debt reduction strategy is similar to other biotech companies that have restructured their debt to improve their financial position, such as Agenus who have renegotiated debt terms.
• The licensing of assets to a regional partner like Brii Bio is a common approach for companies seeking to expand their reach in specific markets, similar to how companies like Gilead have partnered with local companies to commercialize their products in Asia.
• The focus on core pipeline assets is a common strategy for biotech companies looking to streamline operations and focus on their most promising programs, similar to how companies like Biogen have divested non-core assets to focus on their core therapeutic areas.

Stakeholder Impact

• Shareholders will likely view the debt reduction and improved financial stability positively.
• Employees may be impacted by the sale of the Rehovot facility and the transfer of manufacturing responsibilities.
• Customers and partners of VBI may experience changes in manufacturing and supply chain.
• Creditors, particularly K2 HealthVentures, will benefit from the debt reduction.

Next Steps

• VBI needs to complete the 'Essential Activities' to transfer manufacturing responsibilities to Brii Bio.
• The company needs to obtain applicable consents under the License Agreement with Ferring International Center S.A. and SciVac.
• The closing of the transactions is targeted for June 30, 2024.
• VBI will need to manage its remaining debt and continue to develop its core pipeline.

Key Dates

Keywords

VBI Vaccines, Brii Biosciences, debt reduction, manufacturing assets, intellectual property, licensing agreement, VBI-2601, VBI-1901, hepatitis B, glioblastoma, K2 HealthVentures